



ARV Therapies and Therapeutic Strategies

INDEPENDENT REPORTING ON CROI 2017

Comprehensive Expert Review and Discussion of Key Presentations

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


PHASE III SWORD 1&2: SWITCH TO DTG+RPV MAINTAINS VIROLOGIC SUPPRESSION THROUGH 48 WKS

Josep M. Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley Kahl, Elizabeth Blair, Brian Wynn, Kati Vandermeulen, Michael Aboud

Abstract 44LB

Dolutegravir + Rilpivirine for Maintenance of Suppression: Design

Phase III, Randomized, Multicenter, Open-label, Parallel-Group, Non-Inferiority Studies




a. DTG + RPV once daily or 2 NRTIs + INI/PI/NNRTI (CAR).
b. 90% power based on 10% non-inferiority margin (estimated response rate =87%).
Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Baseline Characteristics

	Pooled	
	DTG + RPV (n=513)	CAR (n=511)
Age, mean (SD), y	43.4 (11.1)	43.4 (10.2)
≥50 years, n (%)	147 (29)	142 (28)
Female, n (%)	120 (23)	108 (21)
Race, non-white, n (%)	92 (18)	111 (22)
CD4+ cell count		
≤500 cells/mL, n (%)	165 (32)	149 (29)
>500 cells/mL, n (%)	348 (68)	362 (71)
Baseline 3rd-agent class, n (%)		
PI	133 (26)	136 (27)
NNRTI	275 (54)	278 (54)
INI	105 (20)	97 (19)
Baseline TDF use, n (%)	374 (73)	359 (70)
Duration of ART prior to Day 1, median, months	50.8	52.6

Libre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Snapshot Outcomes at Week 48. ITT-e (Pooled)



DTG+RPV is **non-inferior** to CAR with respect to snapshot in the ITT-E population (<50 c/mL) at Week 48

Libre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Snapshot Outcomes

	Early Switch Phase	
	DTG + RPV (n=513) n (%)	CAR (n=511) n (%)
Virologic success	486 (95)	485 (95)
Virologic non-response	3 (<1)	6 (1)
Data in window not <50 c/mL	0	2 (<1)
Discontinued for lack of efficacy	2 (<1)	2 (<1)
Discontinued while VL not <50 c/mL	1 (<1)	1 (<1)
Change in ART	0	1 (<1)
No virologic data	24 (5)	20 (4)
Discontinued due to AE or death	17 (3)	3 (<1)
Discontinued for other reasons	7 (1)	16 (3)
Missing data during window but on study	0	1 (<1%)

Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Virologic Outcomes

- Low rates of snapshot virologic failures at Week 48 were observed

Early Switch Phase


	DTG + RPV n=513	CAR n=511
Confirmed virologic withdrawal (CVW)	2 (<1%)	2 (<1%)

- One subject on DTG + RPV meeting virologic withdrawal criteria had an NNRTI resistance-associated mutation (K101K/E)
- No INI resistance-associated mutations were identified

Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Virologic Outcomes

- 41-year-old female participant randomized to DTG + RPV
 - Viral Load history: pre-treatment >2 million; at Atripla initiation 968K
 - Documented non adherence leading up to Week 36




Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

DTG + RPV for Maintenance of Suppression: Adverse Events Leading to Withdrawal

	DTG + RPV (n=513)
Subjects with AEs leading to withdrawal from the study	21 (4)
Events Leading to Withdrawal (Subject may report > 1 AE)	
Abdominal distention	2 (<1)
Dyspepsia	2 (<1)
Gastrointestinal haemorrhage	1 (<1%)
Pancreatitis acute	1 (<1%)
Peptic ulcer	1 (<1%)
Headache	1 (<1%)
Tremor	1 (<1%)
Drug-induced liver injury	1 (<1%)
Eosinophilic pneumonia acute	1 (<1%)
Hodgkin's disease	1 (<1%)
Kaposi's sarcoma	1 (<1%)
Plasmablastic lymphoma	1 (<1%)
Anxiety	4 (<1)
Depression	3 (<1)
Insomnia	2 (<1)
Depressed mood	1 (<1)
Panic attack	1 (<1)
Suicidal ideation	1 (<1)


Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

Change in Serum Lipids at Week 48 Pooled Data Early Switch Phase



Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.

Change in Bone Markers at Week 48 Pooled Data Early Switch Phase



*Adjusted for baseline third agent, age, sex, body mass index, smoking status, and baseline biomarker level. Statistical model uses log-transformed data.
Llibre J, et al. 24th CROI; Seattle, WA; February 13-16, 2017. Abst. 44LB.